FINWIRES · TerminalLIVE
FINWIRES

研究快讯:尽管盈利增长强劲,Royal Gold第一季度业绩仍不及预期

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:Royal Gold第一季度营收为4.691亿美元,同比增长143%,但低于市场预期1.5%;调整后每股收益为2.72美元,尽管同比增长80%,但仍比预期低0.03美元。该业绩反映了整合Sandstorm、Horizon和Kansanshi三项收购后的第一个完整季度,这三项收购将于2025年完成。运营现金流达到2.936亿美元,调整后EBITDA利润率为83%。此次变革性收购活动重新调整了公司投资组合,增强了多元化:黄金占比71%,白银占比16%,铜占比10%,业务分布在北美(55%)、南美/中美洲(23%)、欧洲、中东和非洲(EMEA)地区(18%)以及澳大利亚和太平洋地区(3%)。管理层在第一季度偿还了3亿美元债务,使未偿债务余额降至5.25亿美元,目标是在2027年第一季度初全部偿还完毕,同时批准了一项5亿美元的股票回购计划。我们认为,扩大后的投资组合的规模效益和地域多元化能够缓解此前对集中风险的担忧,但具体执行情况取决于更广泛的资产基础中矿业合作伙伴的配合。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661